Pfizer (PFE) Gross Profit Growth (3y) (2012 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Gross Profit Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
44.89% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
3.95% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
9.39% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
4.61% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
10.24% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
3.66% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
1.34% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-2.75% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 29, 2026 |
1.34% |
| Sep 28, 2025 |
-28.32% |
| Jun 29, 2025 |
-27.63% |
| Mar 30, 2025 |
-26.97% |
| Sep 29, 2024 |
-32.80% |
| Jun 30, 2024 |
-5.69% |
| Mar 31, 2024 |
3.54% |
| Oct 1, 2023 |
-42.96% |
| Jul 2, 2023 |
-68.43% |
| Apr 2, 2023 |
-29.16% |
| Oct 2, 2022 |
18.04% |
| Jul 3, 2022 |
21.34% |
| Apr 3, 2022 |
13.63% |
| Oct 3, 2021 |
9.97% |
| Jul 4, 2021 |
4.10% |
| Apr 4, 2021 |
0.05% |
| Sep 27, 2020 |
-7.13% |
| Jun 28, 2020 |
-7.74% |
| Mar 29, 2020 |
-7.57% |
| Sep 29, 2019 |
0.39% |
| Jun 30, 2019 |
2.33% |
| Mar 31, 2019 |
1.71% |
| Dec 31, 2018 |
-68.23% |
| Sep 30, 2018 |
2.43% |
| Jul 1, 2018 |
2.94% |
| Apr 1, 2018 |
4.64% |
| Dec 31, 2017 |
0.10% |
| Oct 1, 2017 |
1.09% |
| Jul 2, 2017 |
-0.24% |
| Apr 2, 2017 |
3.47% |
| Dec 31, 2016 |
-1.09% |
| Oct 2, 2016 |
-1.29% |
| Jul 3, 2016 |
-2.41% |
| Apr 3, 2016 |
0.02% |
| Dec 31, 2015 |
-1.52% |
| Sep 27, 2015 |
-2.49% |
| Jun 28, 2015 |
-5.85% |
| Mar 29, 2015 |
-9.41% |
| Dec 31, 2014 |
1.82% |
| Sep 28, 2014 |
-8.86% |
| Jun 29, 2014 |
-7.23% |
| Mar 30, 2014 |
-10.10% |
| Dec 31, 2013 |
-4.48% |
| Sep 29, 2013 |
-5.33% |
| Jun 30, 2013 |
-7.25% |
| Mar 31, 2013 |
-6.40% |
| Dec 31, 2012 |
-3.23% |
| Sep 30, 2012 |
2.68% |
| Jul 1, 2012 |
7.90% |
| Apr 1, 2012 |
8.67% |